The Technical Analyst
Inozyme Pharma, Inc. [INZY]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Inozyme Pharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.53% $4.51
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 278.59 mill |
| EPS: | -1.370 |
| P/E: | -3.29 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 61.77 mill |
| Avg Daily Volume: | 0.662 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.29 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.56x |
| Company: PE -3.29 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.232 (-105.13%) $-4.74 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.03 - 4.99 ( +/- 10.71%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Treco Douglas A | Sell | 25 000 | Restricted Stock Units |
| 2024-04-01 | Treco Douglas A | Buy | 25 000 | Common Stock |
| 2024-04-02 | Treco Douglas A | Sell | 7 523 | Common Stock |
| 2024-03-28 | Winton Matthew | Buy | 3 188 | Common Stock |
| 2024-03-13 | Winton Matthew | Buy | 175 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 98.01 |
| Last 96 transactions |
| Buy: 18 900 467 | Sell: 34 205 433 |
Forecast:
16:00 - $4.50
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.50
Forecast 2: 16:00 - $4.50
Forecast 3: 16:00 - $4.50
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.51 (-1.53% ) |
| Volume | 0.585 mill |
| Avg. Vol. | 0.662 mill |
| % of Avg. Vol | 88.31 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For INZY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $5.43 | N/A | Active |
|---|
INZY
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2024-04-08 06:30:00 - Press Release
Inozyme Pharma Announces Positive Topline Data From Ongoing Phase 1/2 Trials Of Inz-701 In Adults With Abcc6 Deficiency (pxe) And Enpp1 Deficiency
- favorable safety and immunogenicity profile in abcc6 deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (pros) -
2024-04-05 18:00:00 - Press Release
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Boston, april 05, 2024 (globe newswire) -- inozyme pharma, inc. (nasdaq: inzy) (“company” or “inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to three new employees to purchase shares of the company's common stock, pursuant to the company's 2023 inducement stock incentive plan, as inducement material to the new employees entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4).
2024-04-02 08:30:00 - Press Release
Inozyme Pharma To Participate At The 23rd Annual Needham Virtual Healthcare Conference
Boston, april 02, 2024 (globe newswire) -- inozyme pharma, inc. (nasdaq: inzy) (“the company” or “inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that doug treco, ph.d., the company's chief executive officer and chairman of the board, will participate in a fireside chat at the 23rd annual needham virtual healthcare conference on tuesday, april 9, 2024 from 10:15-10:55 a.m. et.
2024-03-26 08:30:00 - Press Release
Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Trials Of Inz-701 In Adults With Abcc6 Deficiency And Enpp1 Deficiency On April 8, 2024
- company to host conference call and webcast featuring key opinion leaders on monday, april 8, 2024 at 8:00 a.m. et - boston, march 26, 2024 (globe newswire) -- inozyme pharma, inc. (nasdaq: inzy) (“the company” or “inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on monday, april 8, 2024 at 8:00 a.m.
2024-03-12 08:30:00 - Press Release
Inozyme Pharma Reports Full Year 2023 Financial Results And Provides Business Highlights
– topline data from ongoing phase 1/2 trials of inz-701 in adults with abcc6 deficiency and enpp1 deficiency expected in early april –
Latest News
2024-03-26 08:30:00 - GlobeNewsWire
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m.
2023-11-09 08:30:00 - GlobeNewsWire
Inozyme Pharma to Participate in Upcoming Investor Conferences
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company's chief executive officer and chairman of the board, will participate at the following investor conferences:
2023-10-10 13:33:28 - Zacks Investment Research
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-09-05 08:30:00 - GlobeNewsWire
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company's chief executive officer and chairman of the board, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, from 12:00-12:30pm ET.
2023-08-04 10:54:17 - PennyStocks
3 Penny Stocks To Buy According To Insiders In August 2023
Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy speculation and a thirst for significant gains.
2023-06-02 07:30:00 - GlobeNewsWire
Inozyme Pharma to Present at the Jefferies Healthcare Conference
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company's chief executive officer and chairman of the board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023, from 9:30-9:55 a.m. ET.
2023-04-14 08:30:00 - GlobeNewsWire
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company's senior vice president and chief scientific officer, will present recently announced preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency in an oral presentation on Monday, April 17 at the European Calcified Tissue Society Congress (ECTS) in Liverpool, UK.
2023-04-05 22:25:51 - 24/7 Wall Street
Pivotal bioVenture Partners Fund I Now Owns 7.4% of Inozyme Pharma
Fintel reports that Pivotal bioVenture Partners Fund I has filed a 13D/A form with the SEC disclosing ownership of 3.21MM shares of Inozyme Pharma Inc (INZY).
2023-02-21 16:51:49 - Seeking Alpha
Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data
Shares are down 58% over the past year. Enzyme replacement therapy is an attractive area of drug development with less risk than more exotic modalities like gene therapy.
2023-02-21 06:00:00 - PennyStocks
Choosing Penny Stocks for Short Term Trading; 3 Tips
Use these tips for trading penny stocks in the short term The post Choosing Penny Stocks for Short Term Trading; 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.